Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Use of glucagon-Like-Peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs
Functional imaging studies show that GLP-1R agonists blunt neural responses to reward cues in the ventral tegmental area and nucleus accumbens, and retrospective and early prospective data link their use to reduced intake of alcohol and nicotine
Structure: AOD-9604 corresponds to the C-terminal region of the hGH molecule
Here are some examples of GLP-1 agonists: Dulaglutide (marketed as Trulicity) Exenatide (marketed as Byetta and Bydureon) Liraglutide (marketed as Victoza) Lixisenatide (marketed as Adlyxin) Semaglutide (marketed as Ozempic and Rybelsus) Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis: The Glucagon-like Peptide-1 (GLP-1) Agonists Market size is estimated at USD 11.87 billion in 2023, and is expected to reach USD 12.55 billion by 2028, growing at a CAGR of 1.12% during the forecast period (2023-2028)
US$ 22.09
US$ 28.57
US$ 20.90
US$ 23.23
US$ 23.70
US$ 27.00
US$ 20.40
